Press coverage about Acorda Therapeutics (NASDAQ:ACOR) has trended positive recently, according to Alpha One Sentiment. The research group, a unit of Accern, ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a coverage optimism score of 0.28 on Alpha One’s scale. Alpha One also gave news coverage about the biopharmaceutical company an impact score of 75 out of 100, indicating that recent press coverage is likely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have effected Alpha One Sentiment Analysis’s scoring:
- Acorda Therapeutics, Inc.’s (ACOR) registers a price change of -0.32% while ResMed Inc.’s (RMD) finishes with a flow … – Stocks Gallery (stocksgallery.com)
- The Acorda Therapeutics Inc (ACOR) Expected to Post Earnings of $0.12 Per Share – BangaloreWeekly (bangaloreweekly.com)
- Acorda Therapeutics Inc (ACOR) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Acorda Therapeutics, Inc. (NasdaqGS:ACOR) Gross Margin Score in Focus – JCTY News (jctynews.com)
- Acorda Therapeutics, Inc. (NASDAQ:ACOR) Runs -2.18% For the Past 5 Trading Days – Concord Register (concordregister.com)
A number of equities analysts have recently commented on the stock. Janney Montgomery Scott upgraded shares of Acorda Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $23.00 to $38.00 in a research report on Monday, March 13th. Vetr upgraded shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating and set a $30.58 price objective for the company in a research report on Tuesday, March 14th. Stifel Nicolaus restated a “buy” rating and issued a $30.00 price objective on shares of Acorda Therapeutics in a research report on Thursday, March 30th. TheStreet upgraded shares of Acorda Therapeutics from a “d+” rating to a “c-” rating in a research report on Friday, February 17th. Finally, Cantor Fitzgerald reiterated a “positive” rating on shares of Acorda Therapeutics in a research report on Wednesday, February 15th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Acorda Therapeutics currently has an average rating of “Buy” and a consensus price target of $28.26.
Acorda Therapeutics (NASDAQ:ACOR) traded down 0.96% on Tuesday, hitting $15.50. 431,365 shares of the company’s stock traded hands. Acorda Therapeutics has a 12 month low of $15.30 and a 12 month high of $33.00. The stock has a 50 day moving average price of $17.97 and a 200-day moving average price of $20.95. The stock’s market cap is $710.01 million.
Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.08. Acorda Therapeutics had a negative return on equity of 1.66% and a negative net margin of 4.38%. The firm had revenue of $119.39 million for the quarter, compared to analyst estimates of $127.34 million. During the same quarter in the prior year, the company earned $0.28 EPS. Acorda Therapeutics’s revenue was up 3.0% on a year-over-year basis. Equities analysts predict that Acorda Therapeutics will post $1.98 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Acorda Therapeutics (ACOR) Earns Daily Coverage Optimism Score of 0.28” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/05/16/acorda-therapeutics-acor-getting-positive-news-coverage-report-finds-updated-updated-updated.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
What are top analysts saying about Acorda Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics Inc and related companies.